Feeling For the Heat


     
 
 
  October 6, 2011  
  Volume
XIII, Issue 91
 
 

Home Page : www.otcjournal.com

Email Questions or Comments To:
editor@otcjournal.com

To
OTC Journal Members: 


 

Feeling For the Heat

So- where’s the heat? Where are we going to find something hot that everyone is piling into.

Well, Sunday before last I broke my streak. After having 4 nice profitable Sunday ideas in a row, it was inevitable we would have one that didn’t go our way.

Sagebrush Gold (SAGE), picked at $1.03 two Sundays ago, September 25- headed South in pretty short order.

I’m going to keep reminding everyone about the SSLs- in case you were wondering or didn’t get it, SSL is an acronym for Suggested Stop Loss. Every time I publish a new idea, it includes the following:

  • The Entry Level
  • The Target Price
  • The SSL (Suggested Stop Loss)

Of those three, the SSL is probably the most important. I’ve proven I can find great trading wins in penny stocks time and time again. But, just like every market participant, there are going to be time when it simply goes against you.

The key to making money is minimizing the losses. That’s why you need to adhere to the SSLs. In the case of SAGE, the entry level was $1.03. The Target price was $1.50. The SSL was $.90. It’s now almost 2 weeks later, and the stock is trading at $.54.

Prior to SAGE, I covered NYXO, AAGC, TKDN, and GCLL- all of which were great trading wins.

So, if you had traded into SAGE under $1.10, and you sold when it went the other way down to $.90, you’ve taken a small loss, and you’re living to trade another day.

On the Entry Level- Entry levels reasonably close to the original price are fine. On the entry, the key is to avoid big gaps. If I’ve suggested a certain stock when the market is closed, if it gaps up 10% or more from its closing price, wait for it to come back down. They almost always do.

On the Target Price- Sometimes they trade up nicely, but don’t get all the way to the target. Don’t be afraid to lock in some or all profits when the stock is 70% to 80% of the way there.

On the SSL- following this discipline is the key to surviving, making a good total return, and living to trade another day.

So, SAGE was a bust, but I made up for it last Sunday with another feature on Midas Medici (MMED)- the company no one knows about, but will deliver $130 million in revs over the next year.

MMED, which I first featured some time ago at $2.50, made a new all time high of $4 on Monday, albeit on very light volume. When I first covered this stock it had never traded, and no one knew about it. So far, going back a couple of months, we’re up 60% at the all time high. MMED is not your typical stock. On very light volume it could move $.50 to $1 in price very easily. The price is like the weather in Montana- if you don’t like it, wait an hour. It’s happening slowly, but the volume is picking up in MMED.

So, feeling around for the heat, here’s a couple of stocks to watch:

  • I still like MMED for much higher levels. Keep an eye on that one and accumulate on pullbacks. The completion of a major project was announced today.
  • Keep an eye on one of ideas from last spring: Vringo (AMEX: VRNG) looks like it wants to get perky. Announced a deal today with Verizon.
  • Also, keep an eye on SAGE- it sold off so violently in last week’s market drubbing that it might actually end North from here.

I’m going to take this Sunday off, but stay tuned for some very exciting updates next week.

Home Page : www.otcjournal.com

Email Questions or Comments To:

editor@otcjournal.com


  Refer
A Friend
 

If you find the OTC Journal informative
and profitable, please forward our newsletter alert service to like-minded
friends and associates who share similar market interests.


  Ensure
Newsletter Delivery
 

To ensure newsletter delivery, you
can add any additional email
addresses you may have to the OTC Journal Member List. Receiving the OTC
Journal Newsletter in multiple locations is the best way of making sure
you don’t miss the next investing or trading opportunity! For web based
email addresses, the OTC Journal recommends @yahoo.com or @aol.com for
timely and reliable email newsletter delivery.

Note: Your email address will
be kept strictly confidential, and will not be shared with any other entity
for any purpose at any time. If you no longer wish to receive the OTC Journal,
simply follow the instructions located at the bottom of every OTC Journal
Newsletter Edition.


Disclaimer
DISCLAIMER

The OTC Journal Newsletter is an
electronic publication committed to providing our readers with useful information
on publicly traded companies. The Newsletter contracts with publicly traded
companies and receives compensation from them in the form of cash and sometimes
restricted securities as payment for publishing information and opinion
about the company and the trading market for their securities. Principals
of the Newsletter may also purchase or sell securities of the companies
in the open market from time to time. The positions that the Newsletter
or its principals maintain in securities of the companies are disclosed
here (click
here
) and should be considered in making an investment decision regarding
these companies securities.  The Newsletter may be deemed to have
a conflict of interest between its open market activity and positions in
these securities and the timing of and opinions expressed in its publications
concerning these companies.  The publications should not be considered
to be independent publications concerning the company.

All statements and opinions expressed
herein are those of the editors and are subject to change without notice.
The Newsletter maintains editorial control over its publications and the
companies profiled therein do not have any editorial rights concerning
the information published about them. A profile, description, or other
mention of a company in the newsletter is neither an offer nor solicitation
of an offer to buy or sell any securities mentioned. While we believe all
sources of information provided by us and contained in our publication
to be accurate and reliable, we cannot and do not guarantee the accuracy
of information we received from third parties.

READERS  ARE ENCOURAGED TO DO
THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED IN
THIS PUBLICATION. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A
HIGH DEGREE OF RISK.

We encourage our readers to invest
carefully and read the investor information available at the web sites
of the Securities and Exchange Commission (“SEC”) at http://www.sec.gov
and/or the National Association of Securities Dealers (“NASD”) at http://www.finra.org.
We also recommend that you read the SEC advisory to investors concerning
Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm.
Readers can review all public filings by companies at the SEC’s EDGAR page.
The NASD has published information on how to invest carefully at its web
site.

The information found in this profile
is protected by the copyright laws of the united states and may not be
copied, or reproduced in any way without the expressed, written consent
of the editors of otcjournal.com.

 

You can unsubscribe
from this list at any time by Clicking
Here
. If you are having difficulty removing yourself or wish to change
your address please go to http://www.otcjournal.com/opt/?email=$subst(‘Recip.EmailAddr’).
 
     

 

Comments are closed.